Neonatal abstinence and maternal-medicine exposure

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Placental exposure can produce toxicity while drug concentrations remain high, withdrawal as concentrations fall, or a transient adaptation syndrome. Onset depends on half-life, active metabolites, timing of the last maternal dose, gestation and infant metabolism.

Opioids activate fetal receptors and chronic exposure causes neuroadaptation. After birth, abrupt separation from placental drug supply produces autonomic, gastrointestinal and neurological hyperactivity.

Methadone and buprenorphine are evidence-based maternal opioid-substitution treatments. Their presence should not be treated as maternal failure or an automatic reason to stop breastfeeding; stable treatment often improves safety.

SSRIs near delivery are associated with usually self-limiting poor neonatal adaptation, including jitteriness, respiratory difficulty, feeding change and hypoglycaemia. Persistent pulmonary hypertension has a low absolute risk but warrants assessment of significant cyanosis or respiratory distress.

Long-term or near-delivery benzodiazepines may cause neonatal respiratory depression, hypotonia and withdrawal. Diazepam and active metabolites can accumulate because neonatal clearance is slow.

Medicines given during labour, including opioids, magnesium, anaesthetics and sedatives, may explain early depression but must not obscure sepsis, hypoxia, hypoglycaemia or structural disease.

Cannabis, cocaine, amphetamines, alcohol, nicotine and multiple exposures have different fetal and newborn effects; a generic withdrawal score cannot establish which substance caused a sign.

Rooming-in and responsive supportive care reduce stress and often reduce pharmacological treatment. Separating parent and infant can worsen regulation and feeding unless medical or safeguarding needs require it.

When medicine is required, the objective is functional stability, not removal of every tremor or sneeze. Escalation and weaning should follow one current local protocol to avoid dose drift.

Care must integrate maternal pain, addiction, mental health and safeguarding services. Confidential, trauma-informed language improves disclosure and safe planning.

Key points

Use neonatal opioid withdrawal syndrome for opioid-specific withdrawal and neonatal abstinence syndrome when multiple drug classes may contribute; signs are clinical and nonspecific.
Obtain a non-judgemental history of prescriptions, over-the-counter products, substitution therapy, alcohol, nicotine, recreational substances, timing, dose, route and last exposure.
Opioid withdrawal commonly causes high-pitched cry, tremor, irritability, increased tone, poor sleep, yawning, sneezing, sweating, loose stool, vomiting and disorganised feeding.
Late-pregnancy SSRIs can cause transient central, motor, respiratory and gastrointestinal adaptation symptoms; benzodiazepines may cause respiratory depression, floppy infant syndrome or withdrawal.
Do not discontinue an essential maternal medicine abruptly during pregnancy or breastfeeding without specialist advice; maternal relapse and withdrawal can harm both parent and baby.
First-line care is a quiet low-stimulation environment, skin-to-skin contact, swaddling, cue-based frequent feeds, rooming-in and consistent parental involvement.
A function-based assessment asks whether the baby can eat effectively, sleep adequately and be consoled; units may use a validated score but treatment must address function and trend.
Support breastfeeding when maternal treatment is stable and no substance-specific contraindication applies; assess illicit use, HIV status, sedation, co-medication and safeguarding individually.
Use oral morphine only when opioid withdrawal impairs feeding, sleep or consolability despite optimised non-pharmacological care, following one explicit local neonatal protocol.
Phenobarbital may be added by specialists for refractory symptoms or significant non-opioid/polysubstance withdrawal; it does not treat opioid gastrointestinal symptoms as directly.
Toxicology testing supports but does not replace history and examination. Obtain consent, know the detection window and avoid punitive interpretation of a single test.
Discharge requires stable feeding, growth, sleep and cardiorespiratory state, completion of medicine observation after weaning, safe-care planning and coordinated midwifery, primary-care and social follow-up.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Opioid exposure

Methadone, buprenorphine, heroin and prescribed analgesics can produce respiratory toxicity initially and withdrawal as concentrations fall.

Psychotropic medicines

SSRIs and benzodiazepines may cause transient adaptation, sedation, hypotonia or withdrawal depending on timing and half-life.

Polysubstance and peripartum exposure

Alcohol, nicotine, stimulants, cannabis and labour anaesthetic or analgesic medicines create overlapping fetal and neonatal effects.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Neuroadaptation
Chronic receptor exposure changes autonomic and central signalling; abrupt placental separation then produces hyperarousal and gastrointestinal dysfunction.
2
Immature clearance
Neonatal liver and kidney function prolong parent drugs and active metabolites, delaying either toxicity or withdrawal.
3
Regulatory overload
Autonomic activation disrupts sleep, consolability, thermoregulation, sucking and gut motility, increasing energy use and weight loss.
4
Drug-specific toxicity
Opioids and benzodiazepines depress respiration, while stimulants, SSRIs and multiple agents can produce different neurological and cardiovascular effects.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Exposure timeline

Review the maternity and anaesthetic record, UKTIS information and maternal pharmacy list; verify formulation, dose, adherence, last dose and co-exposures rather than using labels such as drug user.

Withdrawal phenotype

Assess alertness, tone, tremor, cry, consolability, sleep, respiratory pattern, temperature, sweating, yawning, sneezing, feeding coordination, vomiting, stool, hydration and weight.

Observed feeding

Observe a complete feed and parent-infant interaction, accounting for prematurity, tongue-tie, illness and normal cluster feeding before attributing difficulty to exposure.

Serial functional assessment

Use the unit's agreed function-based tool or validated score at consistent intervals and after interventions; inter-observer inconsistency makes isolated scores unreliable.

Family safety

Assess maternal sedation, stability, housing, mental health, domestic abuse, other caregivers and safe-sleep capacity with multidisciplinary input and explicit consent processes.

Red flags requiring action

Apnoea, bradycardia, cyanosis or marked sedation soon after birth suggests drug effect, respiratory disease, infection or HIE rather than withdrawal alone.
Seizures, focal neurological signs, bulging fontanelle, persistent abnormal tone or hypoglycaemia requires a full neurological and metabolic assessment.
Fever, poor perfusion, respiratory distress or rising inflammatory concern raises sepsis; irritability and temperature instability are not specific to withdrawal.
Bilious vomiting, abdominal distension, blood in stool, weight loss or dehydration requires urgent gastrointestinal and feeding assessment.
Unexplained bruising, inconsistent exposure history, unsafe caregiving, domestic abuse or parental intoxication prompts proportionate safeguarding assessment while maintaining compassionate care.
Polysubstance exposure, long-acting opioids, benzodiazepines or SSRI exposure may delay or prolong symptoms and require an observation plan tailored to pharmacology.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line: clinical and functional assessmentFirst stepFirst line
Why
Establish whether the baby can feed, sleep, be consoled and maintain physiological stability.
Interpretation and limitations
Serial function and trend determine treatment; no symptom or score confirms exposure, and prematurity can blunt classic withdrawal signs.
02
Point-of-care glucose and basic illness assessment
Why
Exclude common metabolic and infectious mimics of jitteriness, feeding difficulty and altered consciousness.
Interpretation and limitations
Measure glucose promptly with abnormal signs and add sepsis, electrolytes, gas and imaging according to presentation rather than a routine withdrawal panel.
03
Targeted neonatal toxicology
Why
Clarify exposure when results would change medical or safeguarding management.
Interpretation and limitations
Urine reflects a short window; meconium or cord tissue may reflect longer exposure. False positives, prescribed drugs and chain-of-custody issues require laboratory confirmation and consent.
04
Maternal medicine information review
Why
Predict toxicity, onset, duration, breastfeeding transfer and withdrawal risk.
Interpretation and limitations
Use UKTIS, SmPC, pharmacy and specialist services; evidence and recommendations differ by medicine and cannot be inferred from drug class alone.
05
Targeted organ and neurological investigation
Why
Identify alternative pathology in severe, focal or persistent presentations.
Interpretation and limitations
EEG, cranial imaging, cultures, electrolytes, calcium, magnesium and liver tests are selected by signs; treat emergencies while investigating.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Sepsis

Temperature instability, poor feeding, irritability and respiratory signs overlap substantially and require risk-based neonatal cultures, observation and treatment.

Metabolic disturbance

Hypoglycaemia, hypocalcaemia and sodium disorder can cause neonatal jitteriness, seizures, feeding change, irritability and altered muscle tone.

Neurological injury

HIE, stroke, haemorrhage and epilepsy are considered when there is focality, seizures, abnormal consciousness, persistent signs or atypical timing.

Normal or feeding-related behaviour

Cluster feeding, startles, reflux and unsettled neonatal behaviour should be distinguished through direct feeding observation, growth and physiological stability.

Additional chapter-specific clues

Toxicity versus withdrawal

Separate toxicity from withdrawal temporally: early sedation and respiratory depression suggest ongoing effect; later hyperarousal and gastrointestinal signs support withdrawal.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Before birthPlan exposure-aware careFirst stepA medicine or substance with possible newborn effects is identified antenatally.

1Obtain specialist risk assessment without abrupt maternal cessation.
2Agree birth-site, observation, feeding, breastfeeding, maternal analgesia and safeguarding plans.
3Communicate exact exposures confidentially to the neonatal and postnatal teams.

02After birthSupport regulationThe baby is stable but at risk of adaptation or withdrawal.

1Keep parent and baby together where safe, reduce noise and light and use skin-to-skin and swaddling.
2Support frequent cue-based feeds and monitor functional eating, sleeping, consolability, weight and cardiorespiratory state.
3AlternativeUse the unit assessment tool at specified intervals and treat alternative illness promptly.

03EscalationAdd pharmacological treatmentEscalationFunction remains impaired despite optimised supportive care or severe signs occur.

1Confirm opioid withdrawal and review co-exposures and differential diagnoses with senior neonatal staff.
2Start oral morphine through one local weight-based protocol; continue non-pharmacological care and monitor respiratory state.
3Titrate to function, then wean slowly; consider specialist adjunct therapy for refractory or polysubstance signs.

04DischargeMake home care safeSymptoms and feeding are stable and treatment observation is complete.

1Confirm weight trajectory, safe sleep, medication reconciliation and a response plan for feeding or respiratory concerns.
2Coordinate GP, health visitor, maternity, addiction, mental-health and social-care follow-up with parental involvement.
3Document breastfeeding advice and avoid unplanned abrupt maternal or infant medicine changes.

Key medicines and prescribing safety2 treatments · regimens, roles and cautions

Local-protocol first-line pharmacological treatment when opioid withdrawal continues to impair eating, sleeping or consolability despite optimised supportive care.

Morphine sulfate oral solution

One current NHS Greater Glasgow and Clyde neonatal protocol starts 60 micrograms/kg orally every 4 hours for significant opioid withdrawal, increasing by 10 micrograms/kg per dose daily to a maximum 80 micrograms/kg every 4 hours before specialist review and later gradual weaning. Other UK units use different schedules.

This is an explicitly labelled regional example, not a national universal dose. Verify concentration, current weight and local guideline; use independent checks. Monitor sedation, apnoea, oxygenation, feeding and constipation and avoid rapid weaning.

Adjunct rather than routine first-line therapy; may improve central nervous system hyperarousal when opioid replacement alone is insufficient.

Phenobarbital oral or intravenous

Use only the exact neonatal loading, maintenance and level-monitoring regimen in the treating unit's formulary when specialist review identifies refractory symptoms or important non-opioid or polysubstance withdrawal.

Sedation may worsen feeding and obscure neurological illness; respiratory depression and accumulation occur, especially with hepatic dysfunction or concomitant morphine. It does not address all opioid gastrointestinal signs and requires planned weaning.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Feeding and growth failure

Disorganised suck, vomiting, diarrhoea and high energy expenditure can cause neonatal dehydration, excessive weight loss and delayed hospital discharge.

Respiratory compromise

Ongoing maternal drug effect or pharmacological withdrawal treatment can cause neonatal apnoea, hypoventilation, oxygen requirement and aspiration.

Seizures and neurological risk

Severe withdrawal and alternative pathologies can produce seizures; long-term outcome also reflects antenatal adversity and prematurity.

Family and safeguarding harm

Stigma, fragmented services, parental relapse, unsafe sleep and poor follow-up can compound biological risk after discharge.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Observe cardiorespiratory status continuously when sedated, receiving opioid treatment or medically unstable; repeat after every dose change.
Record functional eating, sleep and consolability at consistent intervals and distinguish caregiver report from direct clinical observation.
Trend feed volume or quality, vomiting, stool, urine, hydration and daily weight during the symptomatic period.
Monitor maternal alertness and co-sleeping risk and provide safe-sleep planning without punitive separation.
During morphine titration watch respiratory rate, apnoea, oxygen saturation, sedation, constipation and loss of feeding coordination.
After weaning observe for recurrence for the duration in the local protocol, extended for long-acting or multiple exposures.
Follow growth, development, vision, hearing and family functioning, and ensure the child is linked to routine and enhanced services as indicated.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Exposure is not diagnosis

A documented maternal medicine increases plausibility but does not explain fever, hypoglycaemia, focal seizures or cardiorespiratory collapse without assessment.

Function outranks a number

Treatment targets effective feeding, sufficient sleep and consolability; normal neonatal variation can inflate rigid symptom scores.

Stable substitution therapy is protective

Stopping methadone or buprenorphine abruptly risks maternal withdrawal, relapse and fetal harm and is not a newborn-care strategy.

Breastfeeding is substance-specific

Assess prescribed dose, maternal stability, ongoing illicit use, infant sedation and infections; avoid a blanket ban based on one exposure label.

Language changes safety

Neutral questions about all prescribed and non-prescribed substances improve disclosure and enable a more accurate neonatal plan.

11Common pitfallsFrequent interpretation and management errors.

01
Do not diagnose withdrawal solely from maternal history or one scoring-tool value.
02
Do not miss sepsis, HIE, hypoglycaemia or surgical disease because exposure is known.
03
Do not use naloxone routinely in a chronically opioid-exposed newborn.
04
Do not stop maternal antidepressant, benzodiazepine or substitution therapy abruptly without specialist review.
05
Do not separate parent and infant when rooming-in and support are medically and safeguarding appropriate.
06
Do not use an unlabelled local morphine schedule as though it were a universal national regimen.
07
Do not treat every tremor until absent; aim for stable function and avoid oversedation.
08
Do not discharge without safe-sleep, feeding, medicine, safeguarding and multidisciplinary follow-up plans.